1. Catalog
  2. Nodes
  3. path(MESH:Anxiety)

path(MESH:Anxiety)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
Anxiety
Namespace
MeSH
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns

Appears in Networks 13

albuquerque2009 v1.0.0

This file encodes the article Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function by Albuquerque et al, 2009

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. v1.0.0

This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System v1.0.0

A role for b2* nicotinic receptors in a model of local amyloid pathology induced in dentate gyrus v1.0.0

Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses v1.0.0

Nicotinic Receptor Abnormalities of Alzheimer’s Disease: Therapeutic Implications v1.0.0

Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors. v1.0.0

Tau Modifications v1.9.5

Tau Modifications Sections of NESTOR

Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice v1.0.0

Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons v1.0.0

Chronic Anatabine Treatment Reduces Alzheimer ’ s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD v1.0.0

Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) - a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease v1.0.0

Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP v1.0.0

In-Edges 16

a(CHEBI:nicotine) increases path(MESH:Anxiety) View Subject | View Object

In particular, repeated self-administration produces the upregulation of high-affinity (alpha4beta2) nAChR expression, reduces receptor function due to desensitization and, in most cases, imparts developmental tolerance. Additional changes imposed by nicotine abuse range from reinforcement to physical discomfort associated with withdrawal including craving, anxiety, and a multitude of other less than desirable sensations of autonomic dysfunction when use is stopped. PubMed:19126755

Appears in Networks:
Annotations
Text Location
Review

p(FPLX:CHRN) association path(MESH:Anxiety) View Subject | View Object

Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression. PubMed:17009926

Appears in Networks:

path(MESH:"Alzheimer Disease") increases path(MESH:Anxiety) View Subject | View Object

AD is the most commonly diagnosed form of dementia and currently affects approximately 35 million individuals worldwide.7 AD is a progressive neurodegenerative disease that is characterized by a host of cognitive deficits, including impairments in learning and memory. In addition to the well-documented cognitive impairments, AD patients also display behavioral disturbances, including anxiety, depression, and psychosis PubMed:24511233

Appears in Networks:

p(MGI:App, var("p.Lys670Asn"), var("p.Met671Leu"), var("p.Thr714Ile"), var("p.Val717Ile")) causesNoChange path(MESH:Anxiety) View Subject | View Object

We finally measured anxiety levels using the LDB paradigm. No differences were observed between both groups for the index of time spent in the lit compartment (p = 0.7) as well as for the number of transitions (p = 0.2; Fig. 2GeH) PubMed:27522251

Appears in Networks:
Annotations
MeSH
Dentate Gyrus

bp(GO:"synaptic transmission, cholinergic") association path(MESH:Anxiety) View Subject | View Object

In 2011, we know that cholinergic actions in the brain govern various processes: cognition (attention and executive function) (Couey et al., 2007; Levin and Rezvani, 2007; Heath and Picciotto, 2009; Howe et al., 2010), learning and memory (Gould, 2006; Couey et al., 2007; Levin and Rezvani, 2007), mood (anxiety, depression) (Picciotto et al., 2008), reward (addiction, craving) (Tang and Dani, 2009), and sensory processing (Heath and Picciotto, 2009) PubMed:21482353

Appears in Networks:
Annotations
MeSH
Brain

p(FPLX:CHRN) association path(MESH:Anxiety) View Subject | View Object

The nAChRs are found to be involved in a complex range of central nervous system disorders including Alzheimer’s disease (AD), Parkinson’s disease, schizophrenia, Tourette’s syndrome, anxiety, depression, and epilepsy (Newhouse and Kelton 2000; Newhouse et al 1997; Paterson and Nordberg 2000) PubMed:11230871

Appears in Networks:

p(MESH:"Receptors, Nicotinic") association path(MESH:Anxiety) View Subject | View Object

nAChRs contribute to cognitive function, and changes in their number and/or func- tion are associated with various pathological conditions such as cognitive disorders, anxiety, depression, Alzheimer’s and Parkinson’s disease, pain and epilepsy PubMed:28901280

Appears in Networks:

complex(a(MESH:Nicotine), p(MESH:"Receptors, Nicotinic"), loc(MESH:Brain)) decreases path(MESH:Anxiety) View Subject | View Object

Once in the bloodstream, nicotine, rapidly crosses the blood/brain barrier, and accumulates and exerts its pharmacological effects [9, 58] (including psy- chostimulation, reward and the reduction of stress and anxi- ety) in the brain by binding to nAChRs. PubMed:28901280

Appears in Networks:

a(CHEBI:"(-)-epigallocatechin 3-gallate") decreases path(MESH:Anxiety) View Subject | View Object

Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains. PubMed:28775333

Appears in Networks:
Annotations
MeSH
Alzheimer Disease
MeSH
Down Syndrome

p(MGI:Dyrk1a) positiveCorrelation path(MESH:Anxiety) View Subject | View Object

Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains. PubMed:28775333

Appears in Networks:
Annotations
MeSH
Alzheimer Disease
MeSH
Down Syndrome

a(CHEBI:Anatabine) decreases path(MESH:Anxiety) View Subject | View Object

Tg Tau P301S mice treated with anatabine spent significantly more time (T-test, P<0.05) in the open arms of the elevated plus maze than placebo Tg Tau P301S mice (Figure 3). DOI:10.4172/2168-975X.1000126

Appears in Networks:

path(MESH:"Smoking Cessation") increases path(MESH:Anxiety) View Subject | View Object

(-)-Nicotine withdrawal symptoms might begin within a few hours after the last nicotine product, and include irritability/anger/stress/anxiety, sleep disturbances, depressed mood, craving, cognitive and attention deficits, and increased appetite. PubMed:28391535

Appears in Networks:

a(CHEBI:"amyloid-beta") decreases path(MESH:Anxiety) View Subject | View Object

Transgenic mouse models of AD overexpressing Aβ peptides generally show greater locomotor activity and disinhibition in the elevated plus maze compared to non-transgenic mice, suggest- ing hyperactivity and a lower level of anxiety [28–30]. PubMed:26010758

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(CHEBI:Anatabine) increases path(MESH:Anxiety) View Subject | View Object

The disinhibition affecting Tg PS1/APPswe mice was suppressed following treatment with anatabine at a dosage of either 10 or 20 mg/Kg/Day at both the time points (Figs 2D and 3D). PubMed:26010758

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

p(HGNC:NFKB1) increases path(MESH:Anxiety) View Subject | View Object

p50 knock-out mice exhibit severe deficits in learning as assessed by an active avoidance assay [93] in addition to displaying lack of anxiety-like behavior in well-established tests and paradigms that assess exploratory drive as a measure of anxiety PubMed:28745240

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

p(HGNC:ADNP) decreases path(MESH:Anxiety) View Subject | View Object

Several present with obsessive compulsive behavior, mood disorder, a high anxiety level, temper tantrums, self-injurious and (verbally) aggressive behavior. PubMed:29724491

Appears in Networks:

Out-Edges 5

path(MESH:Anxiety) association p(FPLX:CHRN) View Subject | View Object

Genetic evidence has linked nicotinic receptors to epilepsy and schizophrenia, and studies with mutant mice have implicated nAChRs in pain mechanisms, anxiety, and depression. PubMed:17009926

Appears in Networks:

path(MESH:Anxiety) association bp(GO:"synaptic transmission, cholinergic") View Subject | View Object

In 2011, we know that cholinergic actions in the brain govern various processes: cognition (attention and executive function) (Couey et al., 2007; Levin and Rezvani, 2007; Heath and Picciotto, 2009; Howe et al., 2010), learning and memory (Gould, 2006; Couey et al., 2007; Levin and Rezvani, 2007), mood (anxiety, depression) (Picciotto et al., 2008), reward (addiction, craving) (Tang and Dani, 2009), and sensory processing (Heath and Picciotto, 2009) PubMed:21482353

Appears in Networks:
Annotations
MeSH
Brain

path(MESH:Anxiety) association p(FPLX:CHRN) View Subject | View Object

The nAChRs are found to be involved in a complex range of central nervous system disorders including Alzheimer’s disease (AD), Parkinson’s disease, schizophrenia, Tourette’s syndrome, anxiety, depression, and epilepsy (Newhouse and Kelton 2000; Newhouse et al 1997; Paterson and Nordberg 2000) PubMed:11230871

Appears in Networks:

path(MESH:Anxiety) association p(MESH:"Receptors, Nicotinic") View Subject | View Object

nAChRs contribute to cognitive function, and changes in their number and/or func- tion are associated with various pathological conditions such as cognitive disorders, anxiety, depression, Alzheimer’s and Parkinson’s disease, pain and epilepsy PubMed:28901280

Appears in Networks:

path(MESH:Anxiety) positiveCorrelation p(MGI:Dyrk1a) View Subject | View Object

Treatment with Dyrk1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), from gestation to adulthood suppressed 3R-tau expression and rescued anxiety and memory deficits in Ts65Dn mouse brains. PubMed:28775333

Appears in Networks:
Annotations
MeSH
Alzheimer Disease
MeSH
Down Syndrome

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.